Dna X, Inc. (SONM) intrinsic value & 10-year financials
Dna X, Inc. (SONM) has a Graham intrinsic value of $533.58 per share. At $3.27 on Oct 17, 2026, the stock trades 99% below that value.
- Graham intrinsic value
- $533.58
- Share price (Oct 17, 2026)
- $3.27
- Price vs Graham value
- 99% below
- Market cap
- $2.4M
- Revenue (FY2025)
- —
- Revenue growth (9-yr CAGR)
- -15.1%
- ROIC (10-yr avg)
- -248.4%
- Free cash flow (FY2025)
- —
SONM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$20.7M | -$28.58 | — | — | -587.4% |
| FY2024 | $50.9M | -$33.6M | -$7.13 | -$8.7M | -66.1% | -403.6% |
| FY2023 | $93.6M | -$90.0K | $0.00 | -$4.1M | 0.5% | 3.7% |
| FY2022 | $69.8M | -$14.1M | -$0.49 | -$12.4M | -20.5% | -195.0% |
| FY2021 | $54.6M | -$38.6M | — | -$38.5M | -69.6% | -531.2% |
| FY2020 | $64.0M | -$29.9M | — | -$10.6M | -45.7% | -185.3% |
| FY2019 | $116.3M | -$25.8M | — | -$34.5M | -19.3% | -149.2% |
| FY2018 | $135.7M | $1.3M | — | $3.1M | 4.0% | 60.7% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
DNA X, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
DNA X, Inc. has historically struggled to out-earn its cost of capital, averaging just -13.0% ROIC.
DNA X, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, DNA X, Inc. is modeled at -15.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $533.58 per share.